Genetic material from killed skin cells may drive drug resistance and regrowth in survivors
In skin keratinocytes with impaired p53 control, inherited genetic material from killed cells could drive most extra growth after repeated antimetabolite treatment. Removing acquired sequences should erase added resistance and growth; acceleration explained entirely by survivors’ original traits would reject this account.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
The biological function description is being prepared
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Mobile element or insert
Acquired nuclear DNA
DNA sequences acquired from other cells and incorporated into a cell's nuclear genome
Where this hypothesis actsSurviving skin cells with impaired p53 control after repeated antimetabolite treatment
Hypotheses on this target 1
Gene editing
Silencing
Excision1
Repair
What is proposed
Excision
Remove acquired DNA segments
With whatNot stated in the record
HowNot stated in the record
Possible result
Expected loss of additional drug resistance and accelerated growth after treatment withdrawal
From the recordУдаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Repeated treatment could leave fewer abnormal skin cells at first while making their later return harder to control. The unexpected move is that killed cells might supply genetic material that permanently changes the survivors, rather than treatment merely leaving behind cells already able to withstand it. That is a hypothesis generated by this pipeline, not a measured result.
- Repeated drug treatment kills abnormal cells in the skin's outer layer and releases their DNA.
- Survivors with impaired p53 take up DNA released by the killed cells.
- The acquired DNA changes from material merely present inside a cell into a lasting part of that cell's inherited genetic instructions.
- Acquired sequences combine with the survivor's existing genetic changes to increase its ability to survive the drug.
- The same acquired material increases growth after treatment stops and remains effective when descendants are grown again under shared control conditions.
- These inherited changes are proposed to account for most of the additional growth following repeated treatment.
A workshop salvages pages from another workshop's discarded instruction book and binds them into its own. The new pages then change what it can make, even after the discarded book is gone.
Where the picture breaks: Cells do not deliberately select useful instructions. The picture does not establish that donor DNA enters a survivor's inherited genetic material, functions there, or produces either proposed advantage.
- Master questionstep 01 of 04
A therapy is sought that would bring the skin function of middle-aged people closer to that of young people.
Rests on: The goal sets younger skin function as the desired treatment outcome.
AssumptionThe goal assumes that younger skin function provides a suitable treatment target. The supplied material does not define which functions would be measured or what would count as reaching that target.
- Goal pillarstep 02 of 04
Limiting damage that accumulates during repeated restoration is selected as a route toward better skin function.
Rests on: The goal requires improvement in skin function; this stage introduces accumulated damage from repeated restoration as something that could obstruct it.
AssumptionIt is assumed that repeated restoration contributes damage relevant to the stated goal. The master question does not establish that contribution.
- Gap questionstep 03 of 04
Repeated removal of abnormal cells with an antimetabolite, a drug that interferes with the chemical processes cells need to grow or multiply, might initially reduce affected areas yet accelerate their later occupation by related groups of cells that survive the drug. The question includes whether this effect recurs after treatment stops.
Rests on: The preceding stage identifies cumulative harm from repeated restoration as a concern.
LeapThe supplied chain does not explain why repeated drug removal of abnormal cells is the relevant form of restoration, or supply evidence connecting it to accelerated occupation by surviving cells after treatment. The screened sources do not supply that bridge.
- Hypothesisstep 04 of 04
Killed keratinocytes, the cells that form much of the skin's outer layer, are proposed to release deoxyribonucleic acid (DNA), the molecule that carries genetic information. Surviving cells with impaired p53, a protein involved in controlling responses to cell damage, are proposed to incorporate that material into their own inherited genetic instructions. The acquired material would then increase both survival during treatment and growth after treatment stops, accounting for most of the additional growth after repeated courses.
Rests on: The preceding question supplies repeated killing, surviving cells and later regrowth as the events requiring an explanation. The endpoint supplies an explicit proposed connection between them: acquired genetic material persists in survivors and changes their behavior.
Stated in the chain
What is carried, and what is not. Neither screened source directly supports any of the six proposed links in skin cells. The Science of the Total Environment source from 2025 describes uptake of free DNA by bacteria in wastewater, while the 2020 mBio source reports a computational bacterial model in which acquired genetic material improves survival under changing stress; these are background precedents, not evidence for transfer into skin cells, the proposed role of p53, or the sequence from repeated treatment to lasting faster growth.
Where the reasoning is carried by something unstated · 3
- Master question. The goal assumes that younger skin function provides a suitable treatment target. The supplied material does not define which functions would be measured or what would count as reaching that target.
- Goal pillar. It is assumed that repeated restoration contributes damage relevant to the stated goal. The master question does not establish that contribution.
- Gap question. The supplied chain does not explain why repeated drug removal of abnormal cells is the relevant form of restoration, or supply evidence connecting it to accelerated occupation by surviving cells after treatment. The screened sources do not supply that bridge. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Finding donor DNA inside a surviving cell could be mistaken for a lasting inherited change, although it could reflect donor-cell contamination, two cells merging, or temporarily retained material. What closes it: The proposed inherited labels and reading of DNA from individual cells must establish donor origin and the exact sites where donor material joins the survivor's DNA. Persistence in descendants must accompany the specified checks for contamination, merged cells and altered numbers of chromosomes, the structures that package inherited DNA.
- Survivors could grow faster because treatment selected cells already capable of doing so, or because dying cells continue to release growth-promoting signals. Acquired DNA could accompany that growth without causing it. What closes it: Starting properties of each tracked cell family must be compared with its descendants, and descendants must be grown under shared control conditions. Removing the acquired DNA must reverse both added drug survival and faster growth; a matched control undergoing the same removal procedure without losing that DNA is needed to distinguish this effect from damage caused by the procedure. Establishing that the mechanism explains most additional growth also requires measuring its contribution to total additional growth.
- Failure to detect acquired DNA could be read as disproving the mechanism when the search was too limited to find rare events. What closes it: The ability to detect rare events must be calculated before testing, as the specification requires. No sample size or detection threshold is supplied, so the material does not establish when a negative result would be decisive.
What would make this wrong. The strong claim would fail if the additional growth were fully explained by the starting properties of surviving cell families, or if it disappeared under shared control conditions rather than persisting as an inherited change. The proposed causal link would also fail if verified removal of acquired donor DNA left both added drug survival and faster growth intact, with the removal procedure itself appropriately controlled.
What it would change. If this held, judging repeated treatment only by the initial reduction in abnormal skin areas would miss an inherited source of later regrowth. Work toward younger skin function would need to assess whether treatment creates lasting changes in survivors and whether preventing those changes improves the outcome. Even a positive result in reconstructed skin models, laboratory-built systems that reproduce features of skin, would not establish improved function in middle-aged people; the supplied material also leaves the named outcome SPV_11 undefined.
Sources read · 2
Genetic diversity of dissolved free extracellular DNA compared to intracellular DNA in wastewater treatment plants. · The Science of the total environment · 2025
“Free-exDNA can be taken up by bacteria through transformation, and wastewater treatment plants (WWTPs) are positioned as potential hot spots for genetic contamination.”
Does not settle: Источник описывает поглощение внеклеточной ДНК бактериями в очистных сооружениях. Он не устанавливает перенос или интеграцию ДНК в атипичные кератиноциты, роль p53, устойчивость к антиметаболиту, возобновление роста после лечения или вклад такого механизма в SPV_11.
Bacterial Transformation Buffers Environmental Fluctuations through the Reversible Integration of Mobile Genetic Elements. · mBio · 2020
“In conclusion, in this work, we point out that transformation, which is a widespread trait, allows the transient acquisition of MGEs carrying stress resistance genes, which increases bacterial fitness under stochastic stress exposure.”
Does not settle: Источник описывает трансформацию и устойчивость у бактерий в вычислительной модели. Он не устанавливает захват ядерной ДНК выжившими кератиноцитами, роль p53, устойчивость к антиметаболиту, возобновление роста после лечения или вклад этого механизма в SPV_11.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Can repeated removal of abnormal skin cells accelerate growth of drug-resistant cell families, including after treatment stops?
Original wording · exactly as the pipeline generated it
Может ли повторное удаление атипичных клеток антиметаболитом ускорять последующее заселение кожи устойчивыми клонами, несмотря на первоначальное уменьшение поражений, и воспроизводится ли этот эффект после отмены?
What this question is asking
The question concerns whether repeated treatment can reduce visible skin damage while leaving surviving abnormal cells better able to spread. It asks whether an antimetabolite, a drug that interferes with processes needed for cell growth, repeatedly removes susceptible cells and leaves resistant cell families to occupy the treated skin. The comparison is whether those resistant families expand faster because of repeated treatment, both between courses and after treatment stops, and whether the effect occurs consistently. The question assumes an initial reduction in lesions and proposes that competition during skin repair and cells surviving within hair follicles could reverse that early benefit; the supplied evidence does not establish this sequence.
- Antimetabolite
- A class of drugs that interfere with chemical processes cells need to grow and reproduce. The question concerns whether repeated treatment with such a drug could favor surviving abnormal cells.
- 5-fluorouracil
- The antimetabolite named in the supplied sources. Application to the skin and injection into a lesion are different treatment settings represented in those sources.
- Abnormal or atypical cells
- Cells with features that differ from the usual cells in the tissue. This broad description does not by itself establish that a cell is cancerous or resistant to treatment.
- Clone or cell family
- Cells descended from a shared original cell. Growth of a resistant clone means expansion of that family, rather than simply the return of a visible skin patch.
- Drug resistance
- Reduced susceptibility to a drug's effects. Failure of a treatment to clear a lesion does not by itself establish resistance in a particular cell family.
- Lesion
- An area of visibly or otherwise detectably abnormal tissue. Its disappearance and the disappearance of every abnormal cell are distinct outcomes.
- Regenerative selection
- The proposed process in which some surviving cell families gain an advantage as tissue repairs itself. In this question it is a suggested mechanism, not a finding established by the supplied sources.
- Hair follicle or follicular reservoir
- A hair follicle is the skin structure from which a hair grows. Calling it a reservoir proposes that cells survive there and later spread into surrounding skin; that role is not established here.
- Repopulation
- Cells expanding into an area after other cells have been removed. The question specifically concerns repopulation by resistant abnormal cell families.
- Actinic keratosis
- A skin lesion associated with sun damage that can be a precursor to skin cancer. It is the condition discussed in S1, S2, S4, and S5.
- Topical and field-directed treatment
- Topical treatment is applied to the skin surface. Field-directed treatment covers an affected area rather than targeting only an individual visible lesion.
- Imiquimod
- A skin-applied medicine named alongside 5-fluorouracil in the combination treatment described by S5. That combination's reported potential benefit does not identify why earlier treatment failed.
- Squamous cell carcinoma
- A cancer arising from cells that form surface linings, including the skin. S10 concerns an existing skin cancer, a different setting from prevention across an area of skin.
- Biopsy
- Removal and examination of a tissue sample. In S10, this examination provided the reported evidence of cancer clearance.
- Recurrence
- Return of a condition after it has cleared or improved. Recurrence alone does not reveal which cell family produced it or whether treatment caused resistance.
- RL-3
- An undefined label attached to antimetabolite prevention in the supplied gap detail. The input does not establish what treatment or evidence category it denotes.
Antimetabolite prevention produces mainly short-term clinical benefit, while regenerative selection and follicular reservoirs permit subsequent repopulation that could reverse the long-term effect of repeated courses.
The assumption is that treatment initially reduces visible abnormal skin patches, but surviving cell families gain a growth advantage as the skin repairs itself. Hair follicles, the structures from which hairs grow, are proposed as places where abnormal cells can survive and later spread back into treated skin. If established, this would explain how early improvement could coexist with a worse later outcome.
S10 reports clearance of one patient's cancer and no recurrence during five months of follow-up, establishing only a limited example of an early favorable outcome. S4 suggests that follow-up at six to twelve months might better assess treatment effectiveness and recurrence; it does not demonstrate that benefits are mainly short-lived. S1 and S2 identify established treatment options, while S5 discusses combination treatment after previous therapy failed. None of these supplied excerpts establishes selection of resistant cell families, survival within hair follicles, or reversal of long-term benefit. The evidence supplied is too limited to judge the full premise, and the label RL-3 is not defined.S1S2S4S5S10
The same question asked without the part nothing read establishes:
- Does repeated antimetabolite treatment accelerate the expansion of resistant abnormal skin cell families between courses and after treatment stops?
- How does abnormal skin cell growth after repeated antimetabolite treatment relate to the initial change in visible lesions?
- Faster growth persists after treatment stops Under the proposed mechanism, susceptible cells disappear while resistant survivors expand during repair. If that faster expansion continues after treatment ends and occurs consistently, early lesion reduction would not establish lasting control of abnormal cells. An increase in cancer risk would still require separate evidence.
- Faster growth occurs only between courses Repeated treatment would be associated with faster expansion of resistant survivors while courses continue, but that difference would disappear after treatment stops. This would support a treatment-period effect without establishing a lasting reversal of benefit.
- Repeated treatment does not accelerate growth Removing susceptible cells would not translate into faster expansion of resistant cell families. Early improvement would therefore not be undermined by this particular mechanism, although lasting benefit and cancer risk would remain separate questions.
A reduction in visible lesions measures a different outcome from the later growth of abnormal cell families. Under the proposed mechanism, treatment removes susceptible cells, surviving resistant cells expand during repair, and abnormal tissue returns despite the early improvement. If that sequence occurred, judging treatment solely by early clearance could miss a later adverse effect. If it did not occur, treating recurrence as proof that treatment selected resistant cells would wrongly attribute a mechanism that had not been demonstrated. The supplied material does not connect either outcome to the question's ten-year cancer-risk requirement.
Антиметаболитная профилактика, RL-3, даёт преимущественно краткосрочный клинический эффект; регенеративный отбор и фолликулярные резервуары допускают последующее заселение.
Рост патологических клонов между курсами и после отмены остаётся в заданных пределах; избыточный онкологический риск приемлем на десятилетнем горизонте.
Не проверено, меняют ли повторные курсы знак долгосрочного эффекта через отбор устойчивых клонов, скрытый ранним уменьшением поражений.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Проверяемая гипотеза: повторное уничтожение атипичных кератиноцитов создаёт поток генетического материала, который выжившие клетки с нарушенным контролем p53 могут включать в собственный геном. Приобретённые последовательности образуют новые сочетания с исходными изменениями клетки и повышают одновременно её устойчивость к антиметаболиту и способность размножаться после отмены. Сильное утверждение этой гипотезы состоит в том, что горизонтальное наследование объясняет большую часть дополнительного роста после повторных курсов. Носителем долговременного изменения служит приобретённая ядерная ДНК. Предотвращение её функционального закрепления должно ограничивать связанный с лечением компонент SPV_11.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном. Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно IH_Q_L3_M_G4_1_02 или IH_Q_L3_M_G4_1_03. Одного обнаружения чужой ДНК внутри клетки недостаточно.
Would tell it apart from at least one rival. The prediction specifies observable genomic integration, persistence after environmental changes, loss of both additional resistance and accelerated growth upon removal of the acquired segment, and explicit rejection conditions. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
В реконструированных моделях кожи можно сочетать независимые наследуемые метки клеточных линий, секвенирование отдельных клеток и функциональную проверку приобретённых участков. Потребуются исключение примеси донорских клеток, слияния клеток и временного присутствия поглощённой ДНК, а также контроль числа копий хромосом. Редкость предполагаемых событий делает отрицательный результат информативным только при заранее рассчитанной чувствительности поиска.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном. Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth или Dying cells may speed skin recolonization through prostaglandin E2 release. Одного обнаружения чужой ДНК внутри клетки недостаточно.
- Rival 01 of 02What would separate them
Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth predicts: Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение. После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит this hypothesis; перенос ускорения бесклеточной средой поддержит Dying cells may speed skin recolonization through prostaglandin E2 release.
- Rival 02 of 02Dying cells may speed skin recolonization through prostaglandin E2 release
Not yet published.
What would separate themDying cells may speed skin recolonization through prostaglandin E2 release predicts: Бесклеточная среда, полученная после удаления препарата из модели с продолжающейся гибелью клеток, ускорит рост ранее не леченных контрольных линий. Эффект воспроизведёт измеренная концентрация простагландина E2, а блокирование его рецепторного действия на клетки-реципиенты устранит ускорение. При повторном выращивании выживших линий в свежей среде дополнительное преимущество исчезнет. Ускорение, сохраняющееся после прекращения гибели и продукции простагландина E2, опровергнет эту гипотезу как достаточное объяснение и поддержит наследуемые механизмы this hypothesis или Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
Bergsmedh и соавторы показали, что поглощение апоптотических телец клеток с активированными онкогенами могло передавать опухолевые свойства фибробластам с отсутствующим p53. Это экспериментальное основание для переноса механизма, но не свидетельство его действия при местном лечении кожи человека. [Первичное исследование, PNAS, 2001](https://pmc.ncbi.nlm.nih.gov/articles/PMC33481/).
Канцерогенез кожи и фармакология противоопухолевых средств. Пересмотра потребовал бы учебный раздел «Клональная эволюция опухоли и приобретённая лекарственная устойчивость»: происхождение большинства ускоренно растущих линий после лечения пришлось бы описывать с учётом обмена наследственным материалом между линиями.
Большая часть дополнительного роста после повторных курсов окажется связана с новыми сочетаниями донорской ДНК и генома реципиента; точечное устранение приобретённых участков вернёт рост и чувствительность к исходному уровню при сохранении остальных изменений клетки.
Горизонтальный перенос опухолевой ДНК уже описан, поэтому сам факт такого переноса не является еретическим утверждением. Предлагаемая сильная версия касается его преобладающего вклада в ускоренное заселение фотоповреждённой кожи после повторной местной антиметаболитной терапии. При выполненном поиске подтверждения этой конкретной версии не найдено. Отсутствие соответствующих обзоров во всей литературе не доказано; статус HERETICAL остаётся предварительным по этому критерию.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.